Site icon Riyadh Xpress

India to provide COVID19 Vaccine to Saudi Arabia on behalf of AstraZeneca

oxford vaccine

oxford vaccine

India to provide COVID19 Vaccine to Saudi Arabia on behalf of AstraZeneca, a British drugmaker, one of the companies with the successful vaccine. The Serum Institute of India (SII) will be providing 3 million doses of COVID-19 Vaccine to Saudi Arabia in about a week as per the Chief Executive of AstraZeneca (Told Reuters on Monday, 25th Jan 2021).

India to provide COVID19 Vaccine to Saudi Arabia on behalf of AstraZeneca

The Serum Institute has no plans to supply to Europe, although the company has facing immense pressure after cutting down supply due to production issues in Belgium. “SII, the world’s biggest vaccine manufacturer, has partnered with AstraZeneca, the Gates Foundation, and the Gavi vaccine alliance to make up to a billion doses for poorer countries (Al Arabiya).” The cost of each dose $5.25 to Saudi Arabia.

“We continue to support AstraZeneca wherever they need the support. We are happy to do so,” Chief Executive Adar Poonawalla told Reuters in an interview.

“But we have not been asked to supply any more products for Europe because then that would mean supplies to Africa and India would suffer, and we certainly don’t want that,” he said. “Once I satisfy that I can look at other, richer nations. Six months to a year, that could change.”

“We have our hands full, in fact, with the volumes even we need to supply,” Poonawalla said. “We have been on time and we are able to supply to all these nations.”

Source: Reuters and Al Arabiya

More from Riyadh Xpress

The Cloud Corniche | Abha | Saudi Arabia

Lakes Park | Watch complete directions & details of Lakes Park in Riyadh.

Looking for a refreshing adventure in summers in Riyadh? Watch out the latest video of Ain Heet Cave near Riyadh for hiking.

Stay Safe by following precautionary measures given by the government

Finally, follow Riyadh Xpress’s:

In addition, check out the latest articles by Riyadh Xpress

Check out the most viewed articles

Exit mobile version